Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT05851027

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Thrombopoietin Mimetic Peptide-Fc Fusion Protein for Injection (QL0911) in Chemotherapy- Induced Thrombocytopenia

Sponsor: Qilu Pharmaceutical Co., Ltd.

Conditions Chemotherapy-induced Thrombocytopenia

Interventions QL0911

Updated 3 times since 2023 Last updated: May 5, 2023 Started: Jan 15, 2021 Primary completion: Sep 10, 2021 Completion: Sep 10, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Chemotherapy-induced Thrombocytopenia, this trial is completed. The trial is conducted by Qilu Pharmaceutical Co., Ltd. and has accumulated 3 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qilu Pharmaceutical Co., Ltd.

Data source: Qilu Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China